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Haemonchus contortus is a critical parasite of goats and sheep. Infection by this blood-feeding gastrointestinal
nematode (GIN) parasite has significant health consequences, especially in lambs and kids. The parasite has
developed resistance to virtually all known classes of small molecule anthelmintics used to treat it, giving rise in
some areas to multidrug resistant parasites that are very difficult to control. Thus, new anthelmintics are urgently
needed. Bacillus thuringiensis (Bt) crystal protein 5B (Cry5B), a naturally occurring protein made by a bacterium
widely and safely used around the world as a bioinsecticide, represents a new non-small molecule modality for
treating GINs. Cry5B has demonstrated anthelmintic activities against parasites of monogastric animals,
including some related to those that infect humans, but has not yet been studied in a ruminant. Here we show
that H. contortus adults are susceptible to Cry5B protein in vitro. Cry5B produced in its natural form as a sporecrystal lysate against H. contortus infections in goats had no significant efficacy. However, a new Active Phar
maceutical Ingredient (API) paraprobiotic form of Cry5B called IBaCC (Inactivated Bacterium with Cytosolic
Crystals), in which Cry5B crystals are encapsulated in dead Bt cell wall ghosts, showed excellent efficacy in vitro
against larval stages of H. contortus and relative protein stability in bovine rumen fluid. When given to sheep
experimentally infected with H. contortus as three 60 mg/kg doses, Cry5B IBaCC resulted in significant reductions
in fecal egg counts (90%) and parasite burdens (72%), with a very high impact on female parasites (96%
reduction). These data indicate that Cry5B IBaCC is a potent new treatment tool for small ruminants in the battle
against H. contortus.

1. Introduction
There are many species of gastrointestinal nematodes (GINs) that
parasitize small ruminants, such as sheep and goats. The main GIN group
of concern for producers and veterinarians is the trichostrongyles,
common nematode parasites that cause major production loss and

disease. They possess a direct life cycle, where the adults in the host
produce eggs that are shed in the feces. The eggs develop to third stage
larvae, or L3, in the feces and then circulate into the ambient environ
ment. The infective L3 stage (L3i) is ingested by the host and develops
into an egg-laying adult in the gastrointestinal tract of the animal (Scott
and Sutherland, 2009). One species stands out as particularly
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pathogenic due to the fact it feeds on blood. This parasite, Haemonchus
contortus, is an abomasal species that can cause severe anemia, hypo
proteinemia, weight loss, lethargy, rough hair coats, poor wool/milk/
meat production, and death in heavily infected individuals (Zajac, 2006;
Gilleard, 2013). Lambs and kids are at the greatest risk of developing
disease due to their immature immune response and high rate of
infection from environmental contamination due to peri-parturient egg
production by infected ewes and does (Getachew et al., 2007).
Until recently, this parasite was controlled almost exclusively with
anthelmintics. Unfortunately, the wide and frequent use of these drugs
has created selection pressure that favors individual worms resistant to
these anthelmintics (Kaplan, 2004a). The offspring of the adult parasites
that survive treatment make up greater and greater portions of the worm
population as more treatments are administered, leading to a resistant
population and treatment failures (Jackson and Coop, 2000). Resistance
in small ruminant GINs has been reported to all widely available an
thelmintics, including multidrug resistance (Kaplan, 2004b; Wol
stenholme et al., 2004; Howell et al., 2008; Kaplan and Vidyashankar,
2012). For each major class of anthelmintic, resistance was reported
within a decade of the drug becoming commercially available (Kaplan,
2004b); very recently resistance was seen within a few short years of
introduction of monepantel, which belongs to one of the newest classes
of anthelmintics for H. contortus control (Mederos et al., 2014; Van den
Brom et al., 2015). Thus, anthelmintics involving new mechanisms of
action are needed.
We have shown that the nematode-intoxicating crystal (Cry) protein
Cry5B made by the soil bacterium Bacillus thuringiensis (Bt) has broad in
vivo anthelmintic properties against GINs in monogastric animals (mice,
hamsters, dogs, and pigs (Cappello et al., 2006; Hu et al., 2010a; Urban
et al., 2013; Hu et al., 2018b)). Furthermore, Bt Cry proteins related to
Cry5B are used safely, globally, and extensively as the number one
biological insecticide agent in the world, encompassing ~75% of the
bioinsecticide market and expressed in nearly 100 million hectares of
transgenic crops (Karthickumar and Balasubramanian, 2017; Xiao and
Wu, 2019). The main insecticidal components of Bt are three-domain
Cry proteins, named aptly for their propensity to form large crystals
(Schnepf et al., 1998; de Maagd et al., 2001). Three-domain Cry proteins
are pore-forming proteins that specifically bind to and disrupt the
integrity of the invertebrate gut (Griffitts and Aroian, 2005). There are a
few reports of using Bt against H. contortus, for example, in vitro studies
using a Bt strain expressing Cry5B and a larvicidal study using Cry11Aa
(Kotze et al., 2005; de Lara et al., 2016); however, in all cases there were
caveats (e.g., the strain was not deconvolved to show specific Cry ac
tivity or the doses used were very high).
Here, for the first time, we test the efficacy of Cry5B specifically
against H. contortus. Cry5B was tested in vitro in a larval development
assay and then against adult parasites from an H. contortus strain resis
tant to three classes of anthelmintics (triple anthelmintic resistant).
Following these in vitro studies, recombinant Cry5B spore-crystal lysates
were tested against experimental H. contortus infections in goats. Based
on the results of these studies, a new Active Pharmaceutical Ingredient
containing Cry5B called Inactivated Bacterium with Cytosolic Crystal
(IBaCC, a paraprobiotic) was developed and used to treat sheep exper
imentally infected with H. contortus. Here, we present the results of these
studies, showing that Cry5B has excellent potential to positively impact
sheep health and productivity by targeting H. contortus infections and
reproduction.

#271.
2.2. H. contortus in vitro assays
Parasite eggs were isolated from infected sheep stool as described
(Mes et al., 2007). Egg-to-larval assays (larval development assays) were
carried out as described as for C. elegans and cyathostome eggs (Hu et al.,
2010b, 2018a). Briefly, parasite eggs were placed in S Medium in a
96-well format supplemented with Escherichia coliOP50 and incubated
at 25 ◦ C for seven days. The total number that developed to the L3i stage
were counted. Feces from sheep experimentally mono-infected with
H. contortus were shipped overnight from Virginia Tech to the Aroian
Lab for these studies. Cry5B IBaCC was prepared as described (Li et al.,
2020).
Adult H. contortus (Isolate Hc/2004A originally provided by Dr. Ray
Kaplan under an MTA between the University of Georgia and USDA/
ARS) was isolated from French Alpine goats. This strain is resistant to 3
major classes of anthelmintics 1) benzimidazole (fenbendazole, alben
dazole, others), 2) imidazothiazole/tetrahydropyrimidine (levamisole,
morantel, others) and 3) avermectin (ivermectin, doramectin, others),
and slightly resistant to moxidectin. Three goats each at approximately
three months of age were orally inoculated with a single dose of 5000
H. contortus L3i and maintained for an additional 50 days (primary
infection). At 50 days post inoculation (dpi), the goats were euthanized
and adult worms were screened from the abomasal contents then pan
ned using a glass bowl and fine forceps to remove the worms. Tubes
containing about 20–30 adult worms were placed in 50 ml of RPMI-1640
media with antibiotics after washing by sedimentation at least 10 times
in sterile media and shipped overnight to the Aroian laboratory. In vitro
assays were carried out as described for hookworms using the same
medium, same temperature, and same CO2 concentration with the
addition of 25 mM HEPES pH 7.2 (Cappello et al., 2006; Hu et al., 2012,
2013a) in a 24-well plate with volume of 500 μL, four adult H. contortus
per well, and two wells per dose. Cry5B was purified from spore crystal
lysates as described (Griffitts et al., 2001). Adult parasites were scored
once per day as live/dead as described (dead = no motility even after
repeated touching); (Hu et al., 2013a; Urban et al., 2013).
2.3. In vivo goat study
Male Sire (Boer) x Dam (Kiko x Savanna x Boer) goats 19–28 weeks of
age were purchased locally before relocating to a pasture at the Belts
ville Agricultural Research Center in early spring; the pasture had been
free of livestock for the previous three years. Goats on pasture were
supplemented ad libitum with orchard grass hay. The goats had been
treated with moxidectin by the producer 26 days before shipment and
received a CDT vaccine at 26 and 5 days prior to arrival in Beltsville.
Initial egg counts from feces were evaluated as described (Gasbarre
et al., 2015). Upon arrival in Beltsville, the goats showed strongyle eggs
at <50 eggs per gram of feces or epg in 7 of 24 goats (the remainder had
no strongyle eggs), Moniezia proglottids in 7 of 24, Strongyloides eggs in
10 of 24 goats, Trichuris eggs in 1 of 24 goats and coccidia oocysts in all
samples. The average initial body weight was 27.3 kg (22–34 kg range).
All goats were given a subcutaneous injection of 200 mg of ceftiofur
hydrochloride upon arrival in Beltsville.
Haemonchus contortus L3i were obtained from sheep infected at
Virginia Tech (see below for details) and sent overnight as a suspension
to Beltsville. The goats were each subsequently given an oral inoculation
of 5000 H. contortus L3i per animal two weeks after arrival and place
ment on pasture. Weights and fecal samples were collected after three
weeks to evaluate the acquisition of parasite infection and changes in
weight. The average weight at that time was 26.8 kg (19–33 kg range)
with an average strongyle epg of 5843 (8–21,249 range). Full fecal egg
counts of all relevant time points are given in Fig. S1. Two weeks later,
goats were relocated to an open-aired concrete-surfaced enclosure and
randomly assigned to three groups of eight designated as 1) untreated,

2. Materials and methods
2.1. Animal approvals
All protocols in the study were approved by the Virginia Tech
Institutional Biosafety Committee (IBC, Protocol #17–006) and the
Institutional Animal Care and Use Committee (IACUC, Protocol
#18–135, #18–141) and USDA Beltsville IACUC #12–025 and IBC
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2) Cry5B-SCL-treated twice (40 mg/kg body weight once per day one
day apart) and 3) moxidectin-treated (single dose 0.2 mg/kg body
weight), with groups 2 and 3 inoculated by oral gavage. Cry5B SCL was
prepared as described (Marroquin et al., 2000; Hu et al., 2010a). The
goats were fed orchard grass hay ad libitum and a supplement of pelleted
grain concentrate while on the enclosure.
For oral dosing, animals were manually restrained, and the anthel
mintic suspensions were given with a 50 ml syringe and ball-tipped
inoculating needle. Animals were observed daily for any adverse re
actions; none were seen throughout the course of the study. The nec
ropsy of the goats was conducted over three days between eight and 10
days after moxidectin treatment and after the initial treatment with a
two-dose regimen of Cry5B-SCL based on the logistics of availability of
facilities and personnel. After euthanasia, the contents of the abomasum
and small intestine, a rectal fecal sample, and tissue from the large in
testine were collected. Fecal egg counts (Gasbarre et al., 2015) were
determined from feces taken from the rectum at necropsy. The
abomasum and small intestine contents were evaluated for parasite
burden using a modified agar gel method originally used to detect
luminal parasites of swine (Slotved et al., 1996; Urban et al., 2013). Very
few parasites were found in the contents from the small intestine. Ali
quots of samples of abomasum contents collected from the gel after a 3-h
incubation in normal saline at 37C were examined for worms using a
dissecting microscope and gridded Petri dish. All worms present from
the abomasum contents were identified as adult H. contortus based on
morphologic characteristics.

abomasal contents were unfortunately lost during collection. The
number of worms in the entire 20% aliquot of abomasal contents from
each animal was counted using a dissecting microscope and gridded
Petri dish. All worms present were identified as adult Haemonchus con
tortus based on morphologic characteristics.
2.6. Statistics
All graphs and analyses were generated using GraphPad Prism v. 8.
The comparisons between multiple groups in the goat study were carried
out using one-tailed Dunnett’s multiple comparison test, comparing to
control. The comparison of FEC in the sheep study (Fig. 5B) was carried
out using two-way analysis of variance (mixed-effects analysis Time x
Treatment, as there was one data point missing for one sheep). All
comparisons between two groups were carried out using one-tailed
Mann-Whitney test with the assumption that treatment would reduce
the infection, except for starting FEC for the sheep study (two-tailed
Mann-Whitney to test for equality at the beginning).
3. Results
3.1. Cry5B is active against H. contortus adults in vitro
We first determined if Cry5B on its own was active against
H. contortus. Adult parasites from a triple anthelmintic-resistant strain of
H. contortus maintained at the USDA were isolated from French-Alpine
goats and set up for testing an in vitro dose-response using Cry5B puri
fied from spore-crystal lysates (SCLs) (Griffitts et al., 2001, 2005; Cap
pello et al., 2006). We found that purified Cry5B intoxicates triple
anthelmintic-resistant adult H. contortus (Fig. 1).

2.4. In vitro rumen fluid stability study
Cry5B crystals were isolated from Cry5B IBaCC (Li et al., 2020) and
incubated in duplicate in cow rumen fluid for 12, 24, or 48 h as
described (Goeser, 2008; Goeser et al., 2009; Goeser and Combs, 2009).
Incubations were carried out courtesy of Zinpro Corporation. To deter
mine any percent degradation of Cry5B, the amount of full length Cry5B
was quantitated by SDS PAGE relative to BSA standards and compared to
the total amount used in the in vitro assay.

3.2. Cry5B spore crystal lysate was not effective against H. contortus in
goats
We next tested whether Cry5B spore crystal lysates could be used
against an experimental H. contortus infection in goats. SCLs are formed
when Bt sporulates, producing crystal(s) in the cytosol of the mother
cell. The cell subsequently lyses and releases the crystal(s) and the spore.
SCLs are the form of Bt Cry proteins used in topical applications
worldwide as insecticides (Roh et al., 2007; Koch et al., 2015). Goats
experimentally infected with H. contortus larvae were treated with either
nothing (placebo, negative control), Cry5B SCL (40 mg/kg) given twice
one day apart per os, or a single dose of moxidectin (0.2 mg/kg; positive
control). Moxidectin treatment resulted in a statistically significant drop

2.5. In vivo sheep study
Dorset, Suffolk, and Dorset/Suffolk cross lambs aged 7–8 months
were used for this study. The six female and six castrated male lambs had
been previously pastured but were maintained in housing for the
duration of the study to prevent additional natural H. contortus exposure.
All animals were orally administered albendazole (7.5 mg/kg), iver
mectin (0.2 mg/kg), and levamisole (8.0 mg/kg) sequentially to remove
existing strongylid infection. Sheep were orally inoculated with 10,000
H. contortus L3i six weeks prior to beginning IBaCC treatment. The
H. contortus L3i used for infection were obtained from feces of a sheep
with a monoinfection of H. contortus. Fecal samples were collected once
weekly to determine fecal egg counts (FEC) for each animal. To deter
mine FEC, fecal samples were collected rectally from the sheep and
analyzed using the Mini-FLOTAC® test (University of Naples Federico II,
Naples, Italy) with a detection limit of 5 eggs per gram of feces (EPG).
The day before treatment began, sheep were weighed to determine
the treatment dose required for each animal and divided into experi
mental groups balanced for mean FEC with an equal number of males
and females in each group. Mean FEC was determined using the previous
three weeks FEC data for each sheep. Each animal in the treatment group
received a suspension of 60 mg/kg of Cry5B IBaCC in water, adminis
tered orally by syringe. Animals in the control group received 200 mL of
water orally. Treatments were carried out at approximately the same
time of day on three consecutive days (see Fig. 5A). FEC were deter
mined daily. Fecal samples on Days 1–3 were collected before treatment
was given. On Day 8, the sheep were humanely euthanized. A 20%
aliquot of abomasal contents was collected from each animal. An equal
volume of 10% formalin was used to fix the worms. One control animal’s

Fig. 1. Effects of purified Cry5B on H. contortus adults. Triple anthelminticresistant H. contortus adults were incubated in vitro with varying concentra
tions of purified Cry5B and scored for live or dead (no movement even after
touch). Intoxication in this scoring scheme is seen at 100 and 1000 μg/mL. All
other doses overlapped completely with HEPES control.
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in parasite burdens and fecal egg counts (FEC), while Cry5B SCL treat
ment did not, although both parasite burdens and FEC for Cry5B treated
goats were slightly lower than control (see Fig. 2).
3.3. The paraprobiotic Cry5B IBaCC is effective against H. contortus
larvae and crystals are stable in rumen fluid
We recently developed a new Active Pharmaceutical Ingredient
(API) containing Cry5B called IBaCC for inactivated bacterium with
cytosolic crystal (Fig. 3A (Li et al., 2020)). In this form, Cry5B is
expressed in a sporulation defective Bt strain under control of a
non-sporulating promoter, giving rise to production of a Cry5B crystal
inside a vegetative Bt cell. This vegetative Bt is then inactivated (killed)
with food-grade plant essential oil (monoterpenoid), giving rise to a
dead bacterial cell wall ghost, harboring within its peptidoglycan shell a
Cry5B crystal that is fully bioactive. Such a dead probiotic is known as a
paraprobiotic (Taverniti and Guglielmetti, 2011). An appropriate
negative control for IBaCC is IBa (inactivated bacterium). IBa is identical
to IBaCC in all ways except that the plasmid harboring the Cry5B gene
has no insert (empty vector). The parent Bt strain, plasmid backbone,
and all processing steps are otherwise identical for IBa and IBaCC.
Although we were no longer able to access H. contortus adults for
Cry5B efficacy testing, we were able to obtain fecal samples from
H. contortus-infected sheep to evaluate larval development in vitro in the
presence/absence of Cry5B IBaCC. From these fecal samples, we isolated
parasite eggs and carried out egg to larval development assays in a 96
well format culture system over the course of 7 days as described (Hu
et al., 2018a). Three independent experiments were carried out, looking
to see how many H. contortus eggs developed to the infective L3 stage
(L3i) in 7 days at 28 ◦ C. As shown (Fig. 3B), H. contortus larval devel
opment is exquisitely sensitive to Cry5B IBaCC, showing near complete
(98%) inhibition at 56 ng/mL. These results were confirmed with an
independent batch of IBaCC, showing complete (100%) inhibition of L3i
development at 37.5 ng/mL (Fig. S2).
These results demonstrated that IBaCC was potent against
H. contortus larvae. Since the goat study failed to show an effect of Cry5B
on H. contortus, we were concerned that Cry5B crystals might not be
stable during passage through the rumen. To determine if Cry5B from
IBaCC might be stable in a ruminant, Cry5B crystals isolated from Cry5B
IBaCC were incubated in cow rumen fluid in vitro for 12, 24, and 48 h. No
appreciable degradation was seen at 12 and 24 h (Fig. 4). At 48 h,

Fig. 3. IBaCC. (A) Photomicrograph of IBaCC showing dead Bt cells and
encapsulated crystals (dark inclusions). Scale bar is 5 μM. (B) Efficacy of Cry5B
IBaCC against H. contortus egg-to-larval development showing number of eggs
that developed to the L3i stage over seven days in various concentrations of
Cry5B IBaCC (average of three independent experiments). Each concentration
of IBaCC had a corresponding concentration of IBa (empty vector control
bacteria containing no Cry5B) normalized for OD600. Error bars here and
elsewhere represent standard error of the mean.

Fig. 4. Stability of Cry5B IBaCC crystals in cow rumen fluid. Sodium Dodecyl
Sulfate–Polyacrylamide Gel Electrophoresis (SDS-PAGE) of Cry5B IBaCC crys
tals after incubation for indicated number of hours in cow rumen fluid. Arrow
points to full-length Cry5B protein. Although the input Cry5B was not run on
the gel, relative to the amount of Cry5B put into the rumen fluid, there is no
significant degradation of Cry5B at 12 and 24 h (see methods).

approximately 40% of the Cry5B was degraded, indicating that Cry5B
crystals in IBaCC would be stable up to 24 h in the rumen after ingestion
and passage to the abomasum.
3.4. Cry5B IBaCC is effective against H. contortus infestations in sheep
Fig. 2. Cry5B SCL treatment of H. contortus infected goats (n = 8 per group).
(A) Abomasal H. contortus burdens of goats untreated (control), treated with
Cry5B in SCL, or treated with moxidectin (positive control). Moxidectin treat
ment resulted in a 62% reduction relative to control. (B) Corresponding fecal
egg counts. Moxidectin treatment resulted in an 84% reduction relative to
control. Bar represents the average burden. Numbers shown are P values rela
tive to control.

Based on Cry5B IBaCC efficacy against H. contortus larvae and on
stability studies with Cry5B IBaCC crystals in rumen fluid, we tested the
efficacy of Cry5B IBaCC against H. contortus infections in sheep
(Fig. 5A). Twelve sheep were experimentally inoculated with
H. contortus L3i. Fecal samples were taken and pre-treatment FEC were
determined on the day of treatment with IBaCC. Six sheep were given
233
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Fig. 5. Experimental design and FECs of curative sheep study with IBaCC (n = 6 sheep/group). (A) Experimental design of sheep study. (B) Fecal egg counts (FECs)
over time (eggs per gram of feces) relative to the day of first treatment for control (water) and treated (IBaCC) groups (six sheep per group). FECs were always
determined before treatment on any given day. The difference between fecal egg counts between control and treated groups based on two-way analysis of variance (P
= 0.0009) was significant. (C) Comparison of starting and ending FECs for both groups.

water (placebo control) and six sheep were given 60 mg/kg Cry5B in
IBaCC daily for three consecutive days. Fecal egg counts were deter
mined daily (on days when treatment occurred, fecal samples were
taken before treatment). The sheep were euthanized seven days after the
first treatment to determine the worm burden in the abomasum.
Sharp reductions in FEC were seen within two days after treatment
that was statistically significant (Fig. 5B). Although starting FEC were
similar in both control and treated groups, by the end of the study they
were statistically much lower in the treated group (Fig. 5C). Between
88% and 96% reductions in FEC were seen relative to untreated controls
starting three days after the first treatment.
By the end of the study, parasite burdens in Cry5B IBaCC treated
sheep were significantly reduced 72% relative to infected but untreated
control sheep (Fig. 6A). The larger reduction in FEC relative to reduced
adult worm burden was likely due to a 96% reduction in female worms
versus a 60% reduction in male worms (both statistically significant;
Fig. 6B and C).

4. Discussion
New therapies against H. contortus in small ruminants are desper
ately needed due to the highly pathogenic nature of the parasite and its
propensity for developing anthelmintic drug resistance to small mole
cules. Here, we have shown in vitro that Cry5B protein intoxicates adult
H. contortus parasites and is very potent against H. contortus larval
development (complete inhibition ~50 ng/mL). We have presented data
showing for the first time that a Bt Cry protein, Cry5B, when produced as
part of the paraprobiotic IBaCC (crystal encapsulated within the shell of
an inactivated bacterium), significantly reduced H. contortus infection in
sheep. Three 60 mg/kg doses of Cry5B in IBaCC cleared >70% of the
adult parasites and 96% of the female parasites, which led to a com
parable reduction in parasite FEC. Although three doses were given,
further testing may show that 1–2 doses can achieve a biologically sig
nificant effect that reduces infection transmission. Further dosing
studies to determine the minimal effective dose and development of
formulations to promote delivery to the abomasum and posterior GI
tract are warranted.

Fig. 6. H. contortus abomasal parasite burdens in curative sheep study with IBaCC. (A) Total parasite burdens in control vs IBaCC treated sheep. (B) Male parasite
burdens in control vs IBaCC treated sheep. (C). Female parasite burdens in control vs IBaCC treated sheep. Data from one sheep in the control group was not collected
(see Materials and Methods).
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Our data show that Cry5B crystals from IBaCC will survive the rumen
and that H. contortus adults can ingest Cry5B since they are intoxicated in
vitro. How Cry5B is ingested by H. contortus in the abomasum is an area
for investigation but there is precedent for a blood feeder accessing
Cry5B in vivo with hookworms (Kalkofen, 1970; Cappello et al., 2006;
Hu et al., 2012, 2013b, 2018a, 2018b; Wu et al., 2015; Li et al., 2020).
Although Cry5B IBaCC was effective in H. contortus-infected sheep,
we found that Cry5B delivered as part of Bt spore crystal lysates (SCLs)
had no significant impact on H. contortus infections in goats. The reasons
for these disparate results are yet unclear but could include: 1) differ
ences between goats and sheep; 2) differences in dosing (2 × 40 mg/kg
versus 3 × 60 mg/kg); and/or 3) differences between spore crystal ly
sates and IBaCC and the ability of IBaCC and/or Cry5B crystals in IBaCC
to better survive rumen conditions before entering the abomasum to
intoxicate H. contortus.
The mechanism of action of Cry5B has been studied extensively in
C. elegans and to some extent in hookworms and Ascaris, where the
mechanism of action was shown to be conserved with C. elegans (Cap
pello et al., 2006; Hu et al., 2012; Urban et al., 2013). Cry5B, which is a
three-domain Cry protein, needs to be ingested by the target nematode
to act, following which it binds to invertebrate-specific glyco
sphingolipids on nematode intestinal cells and forms pores, resulting in
intoxication, dysfunction, and death as has been demonstrated in insects
targeted by three-domain Cry proteins (Griffitts et al., 2001, 2003, 2005;
Huffman et al., 2004; Griffitts and Aroian, 2005; Barrows et al., 2007;
Bischof et al., 2008; Kao et al., 2011; Los et al., 2011; Hui et al., 2012).
The mechanism of action against H. contortus is likely the same and can
be subjected to more study in the future (e.g., investigation of Cry5B
binding to H. contortus intestinal glycosphingolipds).
Other studies have examined the impact of Bt and Cry proteins on
H. contortus. One group showed that a Cry5B-containing strain of Bt was
toxic to H. contortus adults and larvae (Kotze et al., 2005). Although this
study did not confirm that the anthelmintic activity was due to Cry5B
since other Cry proteins were also produced by this strain, the level of
toxicity against larvae and adults in vitro was remarkably similar to that
shown here (Figs. 1 and 3), suggesting that Cry5B was likely the active
component in those studies. In other studies, either the toxicity seen (e.
g., against larvae) was 2-3 orders of magnitude less effective than shown
here, or the doses used were not indicated, or the efficacy could not be
attributed to Cry protein (e.g., activity was seen against non-feeding egg
stages or activity seen when soluble fractions were injected by intra
peritoneal or intramuscular routes) (Lopez-Arellano et al., 2002; Lopez
et al., 2006; Linares et al., 2008; Vázquez-Pineda et al., 2010; Sinott
et al., 2012; de Lara et al., 2016; Beena et al., 2019).
One interesting finding here was the higher sensitivity of female
versus male H. contortus in vivo. Since Cry proteins need to be ingested to
intoxicate, this may mean that the females are feeding more than males
or their feeding behavior is more conducive towards ingesting Cry
proteins. The significant difference in size between female and male
worms are consistent with the former. Alternatively, the metabolic re
quirements of egg-producing females may make them more sensitive to
intoxication.
Development of anthelmintic resistance in H. contortus is an impor
tant consideration. In this regard, Cry5B may have some advantages.
Forward genetic screens for resistance showed that it is 3X more difficult
for C. elegans to develop resistance to Cry5B than to benzimidazoles and
nicotinic acetylcholine receptor (nAChR) agonists (Hu et al., 2010b).
Furthermore, Cry5B worked synergistically with nAChR agonists and
showed mutual hyper-susceptibility (e.g., nematodes resistant to nAChR
agonists are hyper-susceptible to Cry5B) (Hu et al., 2010b, 2018a). To
our knowledge, no other anthelmintic combinations showed both these
properties. These data predict that exposure of GI parasites to Cry5B in
combination with anthelmintics like pyrantel, tribendimidine, and le
vamisole would limit the induction of resistance (Hu et al., 2010b,
2018a). Finally, it has been shown that pyramiding (combinations of)
insecticidal Cry proteins can provide significant protection against the

development of resistance by insects, even under high selective pressure
(Roush, 1998; Shelton et al., 2000; Stewart et al., 2001; Cao et al., 2002;
Tabashnik et al., 2003; Zhao et al., 2003; Bates et al., 2005; Yang et al.,
2011). Thus, Cry5B could eventually be combined with other Cry pro
teins to impede the development of parasite resistance by GIN parasites
of livestock and humans.
Our data indicated that Cry5B IBaCC has significant potential to
augment current control strategies against H. contortus infections in
sheep and to overcome parasite resistance to drugs currently used to
control this important parasite of ruminants.
Declarations of interest
None.
Acknowledgements
The support of Veterinary Services at the Beltsville Agricultural
Research Center through Dr. Craig Storozuk and Research Animal Ser
vices through George Bowman, Roxane Macdonald, Andy Covell, and
Jason Evans is appreciated, as is the technical support for isolation of
H. contortus adults by Deborah Hebert and the procurement and man
agement of goats by Donald Carbaugh. Mention of trade names or
commercial products in this publication is solely for the purpose of
providing specific information and does not imply recommendation or
endorsement by the U.S. Department of Agriculture (USDA). The USDA
is an equal opportunity provider and employer.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ijpddr.2020.11.004.
Funding
This project was supported by (1) the National Institutes of Health/
National Institute of Allergy and Infectious Diseases grants
R01AI056189 and R01AI50866 to R.V.A., (2) Agriculture and Food
Research Initiative Competitive Grantno. 2015–11323 from the USDA
National Institute of Food and Agriculture to R.V.A.
References
Barrows, B.D., Haslam, S.M., Bischof, L.J., Morris, H.R., Dell, A., Aroian, R.V., 2007.
Resistance to Bacillus thuringiensis toxin in Caenorhabditis elegans from loss of
fucose. J. Biol. Chem. 282, 3302–3311.
Bates, S.L., Zhao, J.-Z., Roush, R.T., Shelton, A.M., 2005. Insect resistance management
in GM crops: past, present and future. Nat. Biotechnol. 23, 57–62.
Beena, V., Ramnath, V., Girija, D., Karthiayini, K., Sreekumar, K.P., Lakshmanan, B.,
Radhika, R., 2019. Bacillus thuringiensis strains from Western Ghats of India possess
nematocidal property against Haemonchus contortus larvae of goats. Heliyon 5,
e02724.
Bischof, L.J., Kao, C.-Y., Los, F.C.O., Gonzalez, M.R., Shen, Z., Briggs, S.P., van der
Goot, F.G., Aroian, R.V., 2008. Activation of the unfolded protein response is
required for defenses against bacterial pore-forming toxin in vivo. PLoS Pathog. 4,
e1000176.
Cao, J., Zhao, J.-Z., Tang, D., Shelton, M., Earle, D., 2002. Broccoli plants with
pyramided cry1Ac and cry1C Bt genes control diamondback moths resistant to
Cry1A and Cry1C proteins. Theor. Appl. Genet. 105, 258–264.
Cappello, M., Bungiro, R.D., Harrison, L.M., Bischof, L.J., Griffitts, J.S., Barrows, B.D.,
Aroian, R.V., 2006. A purified Bacillus thuringiensis crystal protein with therapeutic
activity against the hookworm parasite Ancylostoma ceylanicum. Proc. Natl. Acad.
Sci. U. S. A. 103, 15154–15159.
de Lara, A.P., Lorenzon, L.B., Vianna, A.M., Santos, F.D.S., Pinto, L.S., Aires Berne, M.E.,
Leite, F.P.L., 2016. Larvicidal activity of Bacillus thuringiensis var. israelensis
Cry11Aa toxin against Haemonchus contortus. Parasitology 143, 1665–1671.
Gasbarre, L.C., Ballweber, L.R., Stromberg, B.E., Dargatz, D.A., Rodriguez, J.M.,
Kopral, C.A., Zarlenga, D.S., 2015. Effectiveness of current anthelmintic treatment
programs on reducing fecal egg counts in United States cow-calf operations. Can. J.
Vet. Res. 79, 296–302.
Getachew, T., Dorchies, P., Jacquiet, P., 2007. Trends and challenges in the effective and
sustainable control of Haemonchus contortus infection in sheep. Review. Parasite 14,
3–14.

235

J. Sanders et al.

International Journal for Parasitology: Drugs and Drug Resistance 14 (2020) 230–236
R., Aroian, R.V., 2020. Recombinant paraprobiotics as a new paradigm for treating
gastrointestinal nematode parasites of humans. https://doi.org/10.1101/2020.09.0
2.278341.
Linares, I.H., Arellano, M.E.L., de Gives, P.M., Hernández, E.L., de la Parra, A.B., 2008.
Lethal activity of two Bacillus thuringiensis strains against Haemonchus contortus
histotropic larvae. Ann. N. Y. Acad. Sci. 1149, 164–166.
Lopez-Arellano, M.E., Flores-Crespo, J., de Gives, P.M., de la Parra, A.B., HerreraRodríguez, D., Liébano-Hernández, E., Vázquez-Prats, V.M., Várgas-Urióstegui, P.,
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